在青霉素过敏的情况下，使用沃克、甲硝唑和西他沙星进行抢救治疗。
rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy.
作者信息
Sue Soichiro, Sasaki Tomohiko, Kaneko Hiroaki, Irie Kuniyasu, Kondo Masaaki, Maeda Shin
机构信息
Department of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.
出版信息
JGH Open. 2021 Jan 23;5(2):307-311. doi: 10.1002/jgh3.12492. eCollection 2021 Feb.
BACKGROUND AND AIM
To assess the efficacy and safety of 7-day rescue treatment consisting of a vonoprazan (VPZ), metronidazole (MNZ), and sitafloxacin (STFX) regimen (VPZ-MNZ-STFX therapy) in patients with penicillin allergy.
METHODS
This was a registered prospective intervention study. Patients with penicillin allergy who were diagnosed with infection and had a history of eradication were eligible for inclusion. Seventeen patients were prospectively treated with VPZ 20 mg bid, MNZ 250 mg bid, and STFX 100 mg bid for 7 days. Safety was evaluated using a questionnaire on adverse effects.
RESULTS
The eradication rate of 7-day VPZ-MNZ-SFTX therapy was 88.2% (95% confidence interval: 63.6-98.5%; = 17) in both intention-to-treat and per-protocol analyses. On the questionnaire, 25% of patients reported experiencing diarrhea, with a score of 2 or 3. All patients undergoing VPZ-MNZ-STFX therapy completed 100% of their medication course.
CONCLUSION
Rescue eradication with VPZ-MNZ-STFX therapy is effective and well tolerated in patients with penicillin allergy (UMIN000016335, jRCTs031180133).
背景与目的
评估由沃克拉唑（VPZ）、甲硝唑（MNZ）和西他沙星（STFX）组成的7天挽救治疗方案（VPZ-MNZ-STFX疗法）在青霉素过敏患者中的疗效和安全性。
方法
这是一项注册前瞻性干预研究。被诊断为感染且有根除治疗史的青霉素过敏患者符合纳入标准。17例患者前瞻性地接受VPZ 20mg每日两次、MNZ 250mg每日两次和STFX 100mg每日两次治疗7天。使用不良反应问卷评估安全性。
结果
在意向性分析和符合方案分析中，7天VPZ-MNZ-SFTX疗法的根除率均为88.2%（95%置信区间：63.6-98.5%；n=17）。在问卷中，25%的患者报告有腹泻，评分为2或3分。所有接受VPZ-MNZ-STFX治疗的患者均完成了100%的疗程。
结论
VPZ-MNZ-STFX疗法的挽救性根除治疗对青霉素过敏患者有效且耐受性良好（UMIN000016335，jRCTs031180133）。
Zotero 插件